Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that primarily regulates glucose homeostasis by activating the GLP-1 signaling pathway. Beyond its glucose-lowering effects, lixisenatide suppresses inflammatory responses by downregulating pro-inflammatory cytokine expression and modulates signaling pathways such as Akt-MEK1/2. Additionally, it alleviates oxidative stress, mitochondrial dysfunction, and apoptosis, demonstrating potential value in research on metabolic diseases and inflammation-related conditions (e.g., diabetes and its complications).

利西拉肽

H2O: 80 mg/mL (16.47 mM), Sonication and heating are recommended.